{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:06:15Z","timestamp":1788815175133,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI52183-04"],"award-info":[{"award-number":["R01AI52183-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaip.2025.02.019","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:23:13Z","timestamp":1740486193000},"page":"979-988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnosing and Managing Drug Reaction With\u00a0Eosinophilia and Systemic Symptoms (DRESS) Amidst Remaining Uncertainty"],"prefix":"10.1016","volume":"13","author":[{"given":"Erika Yue","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-0723","authenticated-orcid":false,"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.02.019_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaip.2025.02.019_bib2","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.jaip.2021.05.008","article-title":"Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System","volume":"9","author":"Bluestein","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.073","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management","volume":"90","author":"Wei","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis","volume":"90","author":"Wei","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.02.019_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/microorganisms11020346","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): focus on the pathophysiological and diagnostic role of viruses","volume":"11","author":"Ramirez","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jaip.2025.02.019_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","article-title":"Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions","volume":"151","author":"Gibson","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.019_bib8","first-page":"4576","article-title":"Renal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of 71 cases","volume":"12","author":"Dagnon da Silva","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jaip.2025.02.019_bib9","first-page":"704","article-title":"\"Heart in DRESS\": cardiac manifestations, treatment and outcome of patients with drug reaction with eosinophilia and systemic symptoms syndrome: a systematic review","volume":"11","author":"Radovanovic","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jaip.2025.02.019_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jamadermatol.2023.4450","article-title":"Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus","volume":"160","author":"Br\u00fcggen","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/cid\/ciac798","article-title":"A\u00a0shorter time to drug reaction with eosinophilia and systemic symptoms (DRESS): redefining beta-lactam-associated DRESS","volume":"76","author":"Waldron","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2025.02.019_bib12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jaip.2016.04.026","article-title":"A\u00a0comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions","volume":"4","author":"Trubiano","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bjd.17835","article-title":"Are drug intradermal tests dangerous to explore cross-reactivity and co-sensitization in DRESS?","volume":"181","author":"Soria","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib14","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/jdv.18100","article-title":"Skin manifestations and clinical features of drug reaction with eosinophilia and systemic symptoms: a retrospective multicentre study of 125 patients","volume":"36","author":"Lee","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.019_bib15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2340\/00015555-1152","article-title":"Multiple follicular pustules as an atypical cutaneous manifestation of drug-induced hypersensitivity syndrome","volume":"91","author":"Ueharaguchi","year":"2011","journal-title":"Acta Der Venereol"},{"key":"10.1016\/j.jaip.2025.02.019_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jamadermatol.2024.1082","article-title":"Drug reaction with eosinophilia and systemic symptoms with pustulosis","volume":"160","author":"Hansen","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib18","series-title":"Other viral diseases. Dermatology","author":"Mancini","year":"2003"},{"key":"10.1016\/j.jaip.2025.02.019_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12016-017-8667-7","article-title":"Current perspectives on erythema multiforme","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.02.019_bib20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib22","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1365-2133.2007.07784.x","article-title":"Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome","volume":"156","author":"Kano","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.12783","article-title":"Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"170","author":"Chi","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib25","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2025.02.019_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module","volume":"7","author":"Wolfson","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2013.03.024","article-title":"Characteristics of liver injury in drug-induced systemic hypersensitivity reactions","volume":"69","author":"Lee","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7863815","article-title":"Pulmonary manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review","volume":"2019","author":"Taweesedt","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jaip.2025.02.019_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/ced.14572","article-title":"Drug rash with eosinophilia and systemic symptoms complicated by haemophagocytic lymphohistiocytosis: is screening required?","volume":"46","author":"Hussain","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib31","doi-asserted-by":"crossref","first-page":"e28657","DOI":"10.1002\/pbc.28657","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS)-associated hemophagocytic lymphohistiocytosis (HLH), an important and underrecognized HLH mimic: a case report","volume":"68","author":"Carter","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaip.2025.02.019_bib32","doi-asserted-by":"crossref","first-page":"28492","DOI":"10.1038\/s41598-024-69054-7","article-title":"Viral reactivation and clinical outcomes in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"14","author":"Chan","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2025.02.019_bib33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archdermatol.2009.195","article-title":"Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome","volume":"145","author":"Asano","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamadermatol.2013.2018","article-title":"Saliva polymerase chain reaction assay for detection and follow-up of herpesvirus reactivation in patients with drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"149","author":"Descamps","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/idoj.idoj_196_21","article-title":"RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DiHS): a comparative analysis","volume":"13","author":"Sasidharanpillai","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaip.2025.02.019_bib36","first-page":"203","article-title":"Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition","volume":"27","author":"Roujeau","year":"2009","journal-title":"Dermatol Sinica"},{"key":"10.1016\/j.jaip.2025.02.019_bib37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2025.02.019_bib38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2217\/pgs-2020-0014","article-title":"Gene expression profiling in allopurinol-induced severe cutaneous adverse reactions in Vietnamese","volume":"21","author":"van Nguyen","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2025.02.019_bib39","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/acs.chemrestox.1c00047","article-title":"Extracellular vesicles from human plasma show a distinctive proteome and miRNome profile in patients with severe cutaneous adverse reactions","volume":"34","author":"Salinas-Jaramillo","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jaip.2025.02.019_bib40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizukawa","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib41","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.jaip.2023.06.065","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: predictive score and outcomes","volume":"11","author":"Mizukawa","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaad.2017.05.041","article-title":"Vancomycin and DRESS: a retrospective chart review of 32 cases in Los Angeles, California","volume":"77","author":"Lam","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib43","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jaip.2023.02.035","article-title":"Drug reaction with eosinophilia and systemic symptoms: a systematic review","volume":"11","author":"Awad","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jamadermatol.2022.3491","article-title":"Predicting DRESS syndrome recurrence\u2014the ReDRESS score","volume":"158","author":"Sharma","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jdv.12419","article-title":"Recurrence of drug-induced reactions in DRESS patients","volume":"29","author":"Picard","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.019_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"Ogawa","year":"2013","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2025.02.019_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1684\/ejd.2014.2477","volume":"25","author":"Miyagawa","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/biom11060847","article-title":"Chemokines in severe cutaneous adverse reactions (SCARs)","volume":"11","author":"Miyagawa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaip.2025.02.019_bib49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2133.2012.10921.x","article-title":"Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome","volume":"167","author":"Saito","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib50","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bjd.13162","article-title":"The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"171","author":"Fujita","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib51","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2021.03.075","article-title":"Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: a prospective case-control study","volume":"85","author":"Choudhary","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib52","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib54","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.jid.2022.05.1059","article-title":"IFN-\u03b3 ELISpot in severe cutaneous adverse reactions to first-line antituberculosis drugs in an HIV endemic setting","volume":"142","author":"Porter","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658593","article-title":"Characterization of T-cell responses to SMX and SMX-NO in co-trimoxazole hypersensitivity patients expressing HLA-B\u221713:01","volume":"12","author":"Pratoomwun","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.02.019_bib56","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jaip.2016.11.011","article-title":"Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance","volume":"5","author":"May","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib57","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B\u221713:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2025.02.019_bib58","first-page":"2839","article-title":"Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review","volume":"30","author":"Maloney","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaip.2025.02.019_bib59","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib60","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2025.02.019_bib61","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cod.14063","article-title":"Skin tests in the work-up of cutaneous adverse drug reactions: a review and update","volume":"86","author":"Barbaud","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2025.02.019_bib62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2022.09.011","article-title":"Utility and safety of skin tests in drug reaction with eosinophilia and systemic symptoms (DRESS): a systematic review","volume":"11","author":"Teo","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A\u221732:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.019_bib64","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaip.2017.09.004","article-title":"The combined utility of ex\u00a0vivo IFN-\u03b3 release enzyme-linked immunoSpot assay and in\u00a0vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions","volume":"6","author":"Trubiano","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1398-9995.2003.00308.x","article-title":"Skin test evaluation in nonimmediate allergic reactions to penicillins","volume":"59","author":"Torres","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.02.019_bib66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/cod.12720","article-title":"Long-term reproducibility of positive patch test reactions in patients with non-immediate cutaneous adverse drug reactions to antibiotics","volume":"76","author":"Pinho","year":"2017","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2025.02.019_bib67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/cod.14090","article-title":"Patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): a literature review","volume":"86","author":"de Groot","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2025.02.019_bib68","doi-asserted-by":"crossref","first-page":"AB115","DOI":"10.1016\/j.jaci.2022.12.364","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) with dual sensitization to both vancomycin and ceftriaxone","volume":"151","author":"Krantz","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.019_bib69","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.jaip.2024.05.045","article-title":"First-line antituberculosis drug challenge reactions in drug reaction with eosinophilia and systemic symptoms syndrome in an HIV endemic setting","volume":"12","author":"Porter","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2018.12.017","article-title":"Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications","volume":"147","author":"Ban","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.02.019_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5415\/apallergy.2014.4.3.156","article-title":"A\u00a0retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy","volume":"4","author":"Thong","year":"2014","journal-title":"Asia Pac Allergy"},{"issue":"2","key":"10.1016\/j.jaip.2025.02.019_bib72","article-title":"Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV\/AIDS in patients with previous history of hypersensitivity to cotrimoxazole","author":"Lin","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2025.02.019_bib73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaip.2013.11.002","article-title":"Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction","volume":"2","author":"Pyle","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib74","first-page":"144","article-title":"Lamotrigine rechallenge after a skin rash. A combined study of open cases and a meta-analysis","volume":"6","author":"Serrani","year":"2013","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.jaip.2025.02.019_bib75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.annder.2021.02.002","article-title":"Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): a monocenter retrospective study of 20 cases","volume":"148","author":"Brin","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.019_bib76","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: a retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib77","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/TP.0000000000001655","article-title":"Acute liver failure\/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors","volume":"101","author":"Ichai","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jaip.2025.02.019_bib78","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib79","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/1346-8138.15294","article-title":"Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"47","author":"Tohyama","year":"2020","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100935","article-title":"The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids","volume":"17","author":"Wang","year":"2024","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.02.019_bib81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib82","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jid.2018.10.048","article-title":"Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptoms syndrome","volume":"139","author":"Tsai","year":"2019","journal-title":"J\u00a0invest Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2025.02.019_bib84","first-page":"666","article-title":"Association of hypogammaglobulinemia with DRESS (drug rash with eosinophilia and systemic symptoms)","volume":"16","author":"Boccara","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib85","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00403-021-02274-3","article-title":"Characterizing DRESS syndrome recurrence: a systematic review","volume":"314","author":"Sharma","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaip.2025.02.019_bib86","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.019_bib87","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jdv.18808","article-title":"Management and treatment outcome of DRESS patients in Europe: an international multicentre retrospective study of 141 cases","volume":"37","author":"Kridin","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.019_bib88","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.02.019_bib89","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1038\/s41467-024-52990-3","article-title":"Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"15","author":"Gibson","year":"2024","journal-title":"Nat Commun"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825001904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825001904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:14:04Z","timestamp":1753226044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825001904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2213219825001904"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.019","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosing and Managing Drug Reaction With\u00a0Eosinophilia and Systemic Symptoms (DRESS) Amidst Remaining Uncertainty","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}